MDL | - |
---|---|
Molecular Weight | 302.33 |
Molecular Formula | C18H14N4O |
SMILES | O=C(NC1=NC2=CC=CC=C2N1)C3=CC=CC(N4C=CC=C4)=C3 |
MKI-1 (5-20 μM) inhibits the activity of MASTL in breast cancer cells
[1]
.
MKI-1 (100 μM, 72 h) inhibits various oncogenic properties of breast cancer cells but showed much weaker effects on the viability of normal breast cells
[1]
.
MKI-1 clearly reduces both serine 62-phosphorylation of c-Myc and total c-Myc, with a decrease in ENSA phosphorylation
[1]
.
MKI-1 (20 μM, 16 h) reduces c-Myc stability through PP2A activation in MCF7 cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis [1]
Cell Line: | MCF7 and T47D cells. |
Concentration: | 5-20 μM. |
Incubation Time: | 24 h. |
Result: |
Inhibited the phosphorylation of ENSA in MCF7 and T47D cells.
Significantly inhibited the phosphorylation of ENSA in mitotic cells. |
MKI-1 (50 mg/kg, ip, twice a week) reduces tumor growth and enhances the radiosensitivity of BT549 xenograft model in response to 6 Gy irradiation compared with the control group, with no notable changes in body weight, suggesting the absence of gross toxicity in the treated mice
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Five-week-old female BALB/c nude mice (BT549 cells) [1] . |
Dosage: | 50 mg/kg. |
Administration: | Twice per week by intraperitoneal (i.p.) injection. |
Result: | Reduced tumor growth. |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 250 mg/mL ( 826.91 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.3076 mL | 16.5382 mL | 33.0764 mL |
5 mM | 0.6615 mL | 3.3076 mL | 6.6153 mL |
10 mM | 0.3308 mL | 1.6538 mL | 3.3076 mL |